Chief Scientific Officer Transitions to Part-Time Role with Reduced Salary
IPSC has more than doubled off its 52-week low of $0.435.
Summary
Century Therapeutics' Chief Scientific Officer, Dr. Chad Cowan, has moved to a part-time position with a reduced salary, signaling a potential shift in scientific leadership or operational focus.
Key Events · Executive and Board Changes · IPSC
-
CSO Role Reduced
Dr. Chad Cowan, Chief Scientific Officer, will now serve on a part-time basis, effective June 15, 2026.
-
Salary Reduction
Dr. Cowan's annual salary has been reduced to $296,150, and he will be eligible for a pro-rated annual performance-based target bonus.
Analysis · IPSC · Life Sciences
The Chief Scientific Officer, Dr. Chad Cowan, has transitioned to a part-time role with a significantly reduced annual salary. For a life sciences company, a change in the CSO's commitment can raise questions about the company's scientific strategy, R&D pipeline focus, or financial management, despite recent capital raises and positive preclinical data.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IPSC was trading at $2.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $393.2M. The 52-week trading range was $0.44 to $3.04. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.